SCHEMBL4564924

SCHEMBL4564924

C/C=C(/O)CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63267 1.00
SCHEMBL6529750 1.00
Water SCHEMBL27399716 0.96
Urea SCHEMBL7643901 0.84 OR51E2 (0.35)
Urea SCHEMBL7643907 0.84 OR51E2 (0.35)
Thioglycolic Acid SCHEMBL27412086 0.80 FFAR3 (0.32)
Methacrylic Acid SCHEMBL27502913 0.78 OR51E2 (0.33)
SCHEMBL12152755 0.74
SCHEMBL22055 0.74
SCHEMBL27890647 0.74 ALDH1A1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572786-B2 Irritable bowel syndrome; tachykinin mediated condition such as schizophrenia, emesis, anxiety, depression, irritable bowel syndrome, circadian rhythm disturbances, pain, neurogenic inflammation, asthma, micturition disorder or nociception JANSSEN PHARMACEUTICA, N.V. (BE) 2009-08-11 US disclosed
EP-1578425-B1 SUBSTITUTED 1-PIPERIDIN-3-YL-4-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2007-11-21 EP disclosed
US-20060252747-A1 Substitituted 1-piperidin-3-yl-piperidin 4-yl-piperazine derivatives and their use as neurokinin auantagonists JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-09 US disclosed
US-4388479-A Process for producing C4 -C10 ethylene alcohols GRYAZNOV VLADIMIR M (SU) 1983-06-14 US disclosed